Page "Evidence-based medicine" Paragraph 59

Sometimes caution errs in the other direction.

Kaiser Permanente did not change its methods of evaluating whether or not new therapies were too " experimental " to be covered until it was successfully sued twice: once for delaying in vitro fertilization treatments for two years after the courts determined that scientific evidence of efficacy and safety had reached the " reasonable " stage ; and in another case where Kaiser refused to pay for liver transplantation in infants when it had already been shown to be effective in adults, on the basis that use in infants was still " experimental.

" Here again, the problem of induction plays a key role in arguments.